Efficacy and Safety of Autologous Tumor-infiltrating Lymphocytes in Treatment of Patients With Advanced or Metastatic Refractory Gynecological Cancer: a Prospective Multicenter One-arm Phase Ⅱ Trial
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 91
- 主要终点
- Objective Response Rate
研究概览
简要总结
Prospective, multicenter, single-arm, open label, interventional basket trial to evaluate autologous tumor-infiltrating lymphocytes (TILs) infusion followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparation for the treatment of patients with advanced or metastatic refractory gynecological cancer including cervical, ovarian, endometrial and breast carcinoma.
详细描述
Autologous tumor-infiltrating lymphocytes (TILs) infusion is highly personalized cancer immunotherapy with strong anti-tumor efficacy and tumor specificity. TILs were extracted from autologous fresh tumor tissues, and after ex vivo stimulation, activation and extensive expansion, are reinfused to patients. TIL-based therapies have only been offered in small phase I/II studies in a few centers and revealed a high objective response rate (ORR) in the treatment of metastatic, recurrent or advanced melanoma, non-small cell long carcinoma and cervical carcinoma. However, the efficacy of TIL-based therapies still needs more clinical trials to prove. In this proposal, a one-arm, open, multicenter, phaseⅠ/Ⅱ trial was designed to evaluate the efficacy and safety of autologous tumor-infiltrating lymphocytes in treatment of patients with advanced or metastatic refractory gynecological cancer including cervical, ovarian, endometrial and breast carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Participants eligible for inclusion in this study must meet all of the following criteria: Signed informed consent must be obtained prior to participation in the study.
- •Aged 18-75 years old at the time of consent
- •Participants are diagnosed with advanced or metastatic cervical cancer, ovarian cancer, endometrial cancer or breast cancer with radiology and pathology confirmation.
- •Failure of two or more Lines of Chemotherapy, or not amenable to curative treatment.
- •At least one resectable lesion (or aggregate of lesions resected) of a minimum 1.5 cm in diameter post-resection to extract TIL
- •At least one measurable target lesion, that can be accurately measured in at least one dimension with longest diameter ≥20 mm, as defined by RECIST v1.1
- •All the chemotherapy or radiotherapy targeting the malignant tumors must be discontinued at least 28 days prior to the tumor resection.
- •No serious abnormality of complete blood count and Cardiac, Liver, and Kidney function
排除标准
- •Participants who have received organ transplantation or prior cell transfer therapy
- •Any active autoimmune disease or history of autoimmune disease, or history of primary immunodeficiency.
- •Patients who are taking systemic steroid therapy
- •Patients with confirmed HIV infection, or other uncontrolled active viral infections, or serious system infections
- •Patients with serious complications of heart, lung, liver, kidney, not suitable for enrollment.
- •Patients with suspicious or confirmed brain metastases of any size and any number.
- •Suffered from any other malignancy within 5 years (except for fully treated in situ malignant such as breast cancer, bladder cancer, cutaneous basal cell carcinoma or squamous cell carcinoma)
- •Patients who are pregnant or breastfeeding
- •Any other conditions judged by the researcher will significantly increase the risk of participation.
结局指标
主要结局
Objective Response Rate
时间窗: Up to 6 months
To evaluate the efficacy of TILs in patients with advanced or metastatic refractory malignant gynecological cancer including cervical, ovarian, endometrial and breast carcinoma based on the objective response rate (ORR) as assessed by the Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
次要结局
- Adverse Events(Up to 60 months)
- Overall Survival(Up to 60 months)
- Disease Control Rate(Up to 60 months)
- Progression-Free Survival(Up to 60 months)